These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19805689)

  • 1. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
    Nachman JB; La MK; Hunger SP; Heerema NA; Gaynon PS; Hastings C; Mattano LA; Sather H; Devidas M; Freyer DR; Steinherz PG; Seibel NL
    J Clin Oncol; 2009 Nov; 27(31):5189-94. PubMed ID: 19805689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.
    Reaman GH; Sposto R; Sensel MG; Lange BJ; Feusner JH; Heerema NA; Leonard M; Holmes EJ; Sather HN; Pendergrass TW; Johnstone HS; O'Brien RT; Steinherz PG; Zeltzer PM; Gaynon PS; Trigg ME; Uckun FM
    J Clin Oncol; 1999 Feb; 17(2):445-55. PubMed ID: 10080584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Seibel NL; Steinherz PG; Sather HN; Nachman JB; Delaat C; Ettinger LJ; Freyer DR; Mattano LA; Hastings CA; Rubin CM; Bertolone K; Franklin JL; Heerema NA; Mitchell TL; Pyesmany AF; La MK; Edens C; Gaynon PS
    Blood; 2008 Mar; 111(5):2548-55. PubMed ID: 18039957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881.
    Hutchinson RJ; Gaynon PS; Sather H; Bertolone SJ; Cooper HA; Tannous R; Wells LM; Heerema NA; Sailer S; Trigg ME;
    J Clin Oncol; 2003 May; 21(9):1790-7. PubMed ID: 12721256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
    Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
    Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
    Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
    N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
    Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
    J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
    Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
    Schrappe M; Aricò M; Harbott J; Biondi A; Zimmermann M; Conter V; Reiter A; Valsecchi MG; Gadner H; Basso G; Bartram CR; Lampert F; Riehm H; Masera G
    Blood; 1998 Oct; 92(8):2730-41. PubMed ID: 9763557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
    Schultz KR; Bowman WP; Aledo A; Slayton WB; Sather H; Devidas M; Wang C; Davies SM; Gaynon PS; Trigg M; Rutledge R; Burden L; Jorstad D; Carroll A; Heerema NA; Winick N; Borowitz MJ; Hunger SP; Carroll WL; Camitta B
    J Clin Oncol; 2009 Nov; 27(31):5175-81. PubMed ID: 19805687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
    Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
    J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
    Salzer WL; Burke MJ; Devidas M; Chen S; Gore L; Larsen EC; Borowitz M; Wood B; Heerema NA; Carroll AJ; Hilden JM; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Cancer; 2018 Mar; 124(6):1150-1159. PubMed ID: 29266189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.
    Malempati S; Gaynon PS; Sather H; La MK; Stork LC;
    J Clin Oncol; 2007 Dec; 25(36):5800-7. PubMed ID: 18089878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
    Rahman AT; Gupta SK; Mannan MA; Nahar K
    Kathmandu Univ Med J (KUMJ); 2012; 10(40):53-9. PubMed ID: 23575054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
    Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
    Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
    Steinherz PG; Seibel NL; Sather H; Ji L; Xu X; Devidas M; Gaynon PS
    Leukemia; 2019 Sep; 33(9):2144-2154. PubMed ID: 30816331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
    Tanimoto M; Miyawaki S; Ino T; Kyo T; Sakamaki H; Naoe T; Hiraoka A; Asou N; Ohshima T; Tsubaki K; Kuriyama K; Ueda T; Minamil S; Okabe K; Saito H; Murakami H; Hirano M; Dohy H; Onozawa Y; Suzuki H; Ohno R
    Int J Hematol; 1998 Dec; 68(4):421-9. PubMed ID: 9885441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
    Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.